Windlas Biotech (NSE:WINDLAS) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Windlas Biotech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Windlas Biotech's Free Cash Flow for the three months ended in Mar. 2024 was ₹0 Mil. Windlas Biotech's Revenue for the three months ended in Mar. 2024 was ₹1,713 Mil. Therefore, Windlas Biotech's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Windlas Biotech's current FCF Yield % is 5.42%.

The historical rank and industry rank for Windlas Biotech's FCF Margin % or its related term are showing as below:

NSE:WINDLAS' s FCF Margin % Range Over the Past 10 Years
Min: -1.93 Med: 2.13 Max: 11.3
Current: 11.3

During the past 6 years, the highest FCF Margin % of Windlas Biotech was 11.30%. The lowest was -1.93%. And the median was 2.13%.

NSE:WINDLAS's FCF Margin % is ranked better than
78.32% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 0.13 vs NSE:WINDLAS: 11.30

Windlas Biotech FCF Margin % Historical Data

The historical data trend for Windlas Biotech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Windlas Biotech FCF Margin % Chart

Windlas Biotech Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

FCF Margin %

Get a 7-Day Free Trial

2.95

1.31

-1.22

-1.93

11.30

Windlas Biotech Quarterly Data
	Mar19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Windlas Biotech's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Windlas Biotech's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Windlas Biotech's FCF Margin % falls into.

Windlas Biotech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Windlas Biotech's FCF Margin for the fiscal year that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2024 )	/	Revenue (A: Mar. 2024 )
	=	712.76	/	6309.56
	=	11.30 %

Windlas Biotech's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	0	/	1712.85
	=	0.00 %

Windlas Biotech FCF Margin % Related Terms

Thank you for viewing the detailed overview of Windlas Biotech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Windlas Biotech (NSE:WINDLAS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Windlas Biotech Ltd (NSE:WINDLAS) » Definitions » FCF Margin %

Traded in Other Exchanges

543329:India

Address

Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001

Website

https://www.windlas.com

Windlas Biotech Ltd is a pharmaceutical formulations contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.

Windlas Biotech (NSE:WINDLAS) Headlines

No Headlines